{
  "Country": "FR",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Progression-free survival, overall survival, objective response rate, quality of life, duration of response, disease control rate"
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line",
      "Intervention": "New medicine under assessment",
      "Comparator": "Ramucirumab + Docetaxel",
      "Outcomes": "Objective response rate, progression-free survival"
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line",
      "Intervention": "New medicine under assessment",
      "Comparator": "Gemcitabine",
      "Outcomes": "Overall survival, quality of life"
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line",
      "Intervention": "New medicine under assessment",
      "Comparator": "Bevacizumab",
      "Outcomes": "Overall survival, quality of life"
    }
  ]
}